Skip to content
BiologicalX

Comparison

Berberine vs Omega-3 (EPA/DHA)

Side-by-side of Berberine and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Berberine

  • Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
  • Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
  • Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
  • Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
  • Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
  • GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side-by-side

Attribute Berberine Omega-3 (EPA/DHA)
Category natural supplement
Also known as berberine HCl, berberine hydrochloride fish oil, EPA, DHA, marine omega-3
Half-life (hr) 3 48
Typical dose (mg) 1500 2000
Dosing frequency 3x daily with meals 1 to 2 times daily with food
Routes oral oral
Onset (hr) 2 4
Peak (hr) 3 12
Molecular weight 336.36 302.45
Molecular formula C20H18NO4+ C20H30O2 (EPA); C22H32O2 (DHA)
Mechanism Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.
Legal status Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia
WADA status allowed allowed
DEA / Rx Not scheduled Not scheduled
Pregnancy Contraindicated (kernicterus risk in neonates) Recommended at 200 to 600 mg DHA/day for fetal development
CAS 2086-83-1 10417-94-4
PubChem CID 2353 446284
Wikidata Q411435 Q207688

Safety profile

Berberine

Common side effects

  • constipation
  • diarrhea
  • abdominal cramping
  • flatulence
  • nausea

Contraindications

  • pregnancy
  • lactation
  • neonatal jaundice
  • severe liver disease

Interactions

  • metformin: additive HbA1c reduction; additive GI side effects(moderate)
  • insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
  • statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
  • cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
  • calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Berberine is the right call when one of the conditionals below applies.

  • If your priority is metabolic health and glucose control, pick Berberine.
  • If your priority is focus or working memory, pick Omega-3 (EPA/DHA).
  • If your priority is healthspan extension, pick Omega-3 (EPA/DHA).

Edge case: Berberine is contraindicated in pregnancy; Omega-3 (EPA/DHA) is the safer pick if that applies.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Berberine only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Berberine and Omega-3 (EPA/DHA)?

Berberine and Omega-3 (EPA/DHA) differ in category (natural vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Berberine or Omega-3 (EPA/DHA)?

Berberine half-life is 3 hours; Omega-3 (EPA/DHA) half-life is 48 hours.

Can you stack Berberine with Omega-3 (EPA/DHA)?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper